Hologic is a medical instruments & supplies business based in the US. Hologic shares (HOLX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $71.19 – an increase of 1.74% over the previous week. Hologic employs 6,990 staff and has a trailing 12-month revenue of around $4 billion.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $71.19 |
|---|---|
| 52-week range | $68.61 - $84.67 |
| 50-day moving average | $76.02 |
| 200-day moving average | $77.48 |
| Wall St. target price | $85.44 |
| PE ratio | 20.7078 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $3.32 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $70.37 from 2025-01-21
| 1 week (2025-01-15) | 2.36% |
|---|---|
| 1 month (2024-12-23) | -2.94% |
| 3 months (2024-10-23) | -13.50% |
| 6 months (2024-07-22) | -10.22% |
| 1 year (2024-01-22) | -4.96% |
|---|---|
| 2 years (2023-01-20) | -11.66% |
| 3 years (2022-01-21) | 70.63 |
| 5 years (2020-01-22) | 29.74% |
Valuing Hologic stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Hologic's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Hologic's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 21x. In other words, Hologic shares trade at around 21x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Hologic's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.8641. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Hologic's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Hologic's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.2 billion.
The EBITDA is a measure of a Hologic's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $4 billion |
|---|---|
| Operating margin TTM | 24.36% |
| Gross profit TTM | $2.4 billion |
| Return on assets TTM | 6.45% |
| Return on equity TTM | 13.85% |
| Profit margin | 17.59% |
| Book value | $21.94 |
| Market Capitalization | $15.6 billion |
TTM: trailing 12 months
We're not expecting Hologic to pay a dividend over the next 12 months.
Hologic's shares were split on a 2:1 basis on 2 April 2008 . So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Hologic shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Hologic shares which in turn could have impacted Hologic's share price.
Over the last 12 months, Hologic's shares have ranged in value from as little as $68.61 up to $84.67. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Hologic's is 0.986. This would suggest that Hologic's shares are less volatile than average (for this exchange).
Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, and specimen radiology solutions; and breast conserving surgery products. In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, it offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Find out more about this component of your brokerage account and how you can use this cash.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.